Adage Capital Partners’s AbbVie ABBV Stock Holding History

Adage Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$320M	Sell	1,470,271 -38,444	-3%	-$8.53M	0.49%	29
2025 Q4	$345M	Sell	1,508,715 -336,077	-18%	-$76.6M	0.52%	25
2025 Q3	$427M	Buy	1,844,792 +225,951	+14%	+$46M	0.68%	20
2025 Q2	$300M	Sell	1,618,841 -179,892	-10%	-$33.4M	0.51%	27
2025 Q1	$377M	Buy	1,798,733 +69,368	+4%	+$13.5M	0.7%	22
2024 Q4	$307M	Buy	1,729,365 +71,582	+4%	+$13.2M	0.54%	28
2024 Q3	$327M	Buy	1,657,783 +237,503	+17%	+$44.3M	0.58%	25
2024 Q2	$244M	Sell	1,420,280 -986,865	-41%	-$163M	0.45%	31
2024 Q1	$438M	Buy	2,407,145 +27,904	+1%	+$4.81M	0.83%	15
2023 Q4	$369M	Buy	2,379,241 +364,424	+18%	+$53.1M	0.76%	20
2023 Q3	$300M	Buy	2,014,817 +498,978	+33%	+$73.3M	0.68%	21
2023 Q2	$204M	Buy	1,515,839 +466,069	+44%	+$68.3M	0.44%	37
2023 Q1	$167M	Sell	1,049,770 -141,253	-12%	-$21.6M	0.38%	49
2022 Q4	$192M	Sell	1,191,023 -563,623	-32%	-$86.4M	0.46%	31
2022 Q3	$235M	Buy	1,754,646 +140,475	+9%	+$20.2M	0.58%	21
2022 Q2	$247M	Sell	1,614,171 -606,900	-27%	-$92.7M	0.57%	27
2022 Q1	$360M	Buy	2,221,071 +237,200	+12%	+$34.5M	0.68%	19
2021 Q4	$269M	Buy	1,983,871 +533,700	+37%	+$63M	0.48%	34
2021 Q3	$156M	Sell	1,450,171 -685,440	-32%	-$78.3M	0.31%	67
2021 Q2	$241M	Sell	2,135,611 -46,200	-2%	-$5.2M	0.47%	34
2021 Q1	$236M	Sell	2,181,811 -186,800	-8%	-$20M	0.48%	37
2020 Q4	$254M	Sell	2,368,611 -349,100	-13%	-$33.5M	0.55%	27
2020 Q3	$238M	Buy	2,717,711 +695,400	+34%	+$65.5M	0.6%	27
2020 Q2	$199M	Buy	+2,022,311	New	+$178M	0.51%	32
2019 Q4	–	Sell	-1,037,161	Closed	-$78.5M	–	713
2019 Q3	$78.5M	Sell	1,037,161 -364,201	-26%	-$25M	0.19%	135
2019 Q2	$102M	Buy	+1,401,362	New	+$110M	0.25%	104
2019 Q1	–	Sell	-388,962	Closed	-$35.9M	–	688
2018 Q4	$35.9M	Sell	388,962 -116,300	-23%	-$10.2M	0.1%	229
2018 Q3	$47.8M	Sell	505,262 -511,400	-50%	-$48.5M	0.11%	229
2018 Q2	$94.2M	Sell	1,016,662 -1,052,661	-51%	-$103M	0.22%	116
2018 Q1	$196M	Sell	2,069,323 -100,545	-5%	-$11M	0.46%	48
2017 Q4	$210M	Sell	2,169,868 -363,500	-14%	-$34.3M	0.47%	47
2017 Q3	$225M	Buy	2,533,368 +135,036	+6%	+$10.3M	0.55%	38
2017 Q2	$174M	Buy	2,398,332 +215,200	+10%	+$14.5M	0.43%	47
2017 Q1	$142M	Buy	2,183,132 +227,100	+12%	+$14.3M	0.36%	71
2016 Q4	$122M	Buy	1,956,032 +120,300	+7%	+$7.34M	0.33%	74
2016 Q3	$116M	Sell	1,835,732 -597,300	-25%	-$38.7M	0.32%	82
2016 Q2	$151M	Sell	2,433,032 -201,600	-8%	-$12.3M	0.41%	72
2016 Q1	$150M	Buy	2,634,632 +348,015	+15%	+$19.4M	0.41%	69
2015 Q4	$135M	Sell	2,286,617 -35,358	-2%	-$2.04M	0.36%	79
2015 Q3	$126M	Sell	2,321,975 -30,900	-1%	-$2.01M	0.35%	71
2015 Q2	$158M	Buy	2,352,875 +42,000	+2%	+$2.74M	0.39%	60
2015 Q1	$135M	Sell	2,310,875 -42,000	-2%	-$2.54M	0.33%	85
2014 Q4	$154M	Buy	+2,352,875	New	+$148M	0.38%	71
2014 Q3	–	Sell	-3,478,442	Closed	-$196M	–	708
2014 Q2	$196M	Buy	3,478,442 +51,600	+2%	+$2.71M	0.51%	46
2014 Q1	$176M	Buy	3,426,842 +570,650	+20%	+$28.8M	0.48%	44
2013 Q4	$151M	Sell	2,856,192 -120,000	-4%	-$5.9M	0.4%	59
2013 Q3	$133M	Buy	2,976,192 +672,800	+29%	+$29.8M	0.38%	70
2013 Q2	$95.2M	Buy	+2,303,392	New	+$101M	0.29%	91

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners's ABBV Position: Q1 2026 in Review

Adage Capital Partners reduced its AbbVie (ABBV) stake by 2.5% in Q1 2026, selling an estimated $8.53M and leaving 1,470,271 shares worth $320M. The position accounts for 0.49% of the portfolio, ranked #29.

Adage Capital Partners first reported a position in ABBV in Q2 2013 and has held it in 48 quarters since. The position peaked at $438M in Q1 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Adage Capital Partners held 1,470,271 shares of AbbVie worth $320M as of Q1 2026.
Adage Capital Partners sold 38,444 AbbVie shares in Q1 2026, an estimated $8.53M.
AbbVie made up 0.49% of Adage Capital Partners's portfolio in Q1 2026, its #29 holding.
Adage Capital Partners first reported a position in AbbVie in Q2 2013 and has held it in 48 quarters since.
Adage Capital Partners's AbbVie position peaked at $438M in Q1 2024.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.